Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound medicine composition taking isoliensinine and chemotherapeutic medicine as active ingredients

A technology of isoliensinine and chemotherapeutic drugs, applied in the field of compound compositions, can solve problems such as no combined application of IsoL, achieve good application prospects and the effect of inhibiting cell viability

Active Publication Date: 2022-05-27
NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is no report on the combined application of IsoL with other drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound medicine composition taking isoliensinine and chemotherapeutic medicine as active ingredients
  • Compound medicine composition taking isoliensinine and chemotherapeutic medicine as active ingredients
  • Compound medicine composition taking isoliensinine and chemotherapeutic medicine as active ingredients

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046]Effects of IsoL combined with Ara-C on the viability of human acute leukemia cells

[0047] The inhibitory effect of IsoL combined with Ara-C on the viability of human acute leukemia cells at 48h was determined by MTT assay. figure 1 As shown, compared with Ara-C alone group, IsoL combined with Ara-C can significantly inhibit the growth of Jurkat, U937 and THP1 cells. After 1 and 2 μmol / L IsoL combined with 0.5, 1 and 2 μmol / L Ara-C, respectively, on Jurkat cells, the CI ranges were 0.1≤CI<0.3, indicating that the two drugs had strong synergistic effects (Table 2).

[0048] Table 2. Analysis of combination index (CI) of IsoL combined with Ara-C on acute leukemia cell line Jurkat

[0049] IsoL(μmol / L) Ara-C(μmol / L) CI 1.0 0.5 0.20053 1.0 1.0 0.18085 1.0 2.0 0.29935 2.0 0.5 0.10571 2.0 1.0 0.18123 2.0 2.0 0.27733

[0050] When acting on U937 cells, among them, after 1 and 2 μmol / L IsoL combined with 8 μmol / L Ara-C, or...

Embodiment 2

[0058] Effects of IsoL combined with DOX on the viability of human acute leukemia cells

[0059] The inhibitory effect of IsoL combined with DOX on the viability of human acute leukemia cells at 48h was determined by MTT assay. figure 2 As shown, IsoL combined with DOX can significantly inhibit the growth of Jurkat and U937 cells compared with DOX alone group. 1 and 2μmol / LIsoL combined with 0.0625, 0.125 and 0.25μmol / L DOX on Jurkat and U937 cells, respectively. The results in Jurkat showed that, except that 2 μmol / L IsoL combined with 0.25 μmol / L DOX produced a strong synergistic effect (0.1≤CI<0.3), the synergistic effects of other concentrations were stronger (Table 5).

[0060] Table 5. CI analysis of IsoL combined with DOX on acute leukemia cell line Jurkat

[0061] IsoL(μmol / L) DOX(μmol / L) CI 1.0 0.0625 0.49275 1.0 0.125 0.42451 1.0 0.25 0.58805 2.0 0.0625 0.38116 2.0 0.125 0.32132 2.0 0.25 0.29241

[0062] In U9...

Embodiment 3

[0067] Effects of IsoL combined with DNR on the viability of human acute leukemia cells

[0068] The inhibitory effect of IsoL combined with DNR on the viability of human acute leukemia cells at 48h was determined by MTT assay. image 3 As shown, compared with DNR alone group, IsoL combined with DNR can significantly inhibit the growth of Jurkat and U937 cells. After 1 and 4 μmol / L IsoL combined with 0.031, 0.0625 and 0.125 μmol / L DNR, respectively, on Jurkat, 4 μmol / L IsoL and 0.031 μmol / L DNR produced strong synergistic effects (0.1≤CI<0.3), and the other concentrations produced strong synergistic effects. Synergy (0.3≤CI<0.7) (Table 7).

[0069] Table 7. CI analysis of IsoL combined with DNR on acute leukemia cell line Jurkat

[0070] IsoL(μmol / L) DNR(μmol / L) CI 1.0 0.031 0.31611 1.0 0.0625 0.45699 1.0 0.125 0.65858 4.0 0.031 0.20757 4.0 0.0625 0.38218 4.0 0.125 0.35379

[0071] On U937 cells, 1 μmol / L IsoL and 0.0625...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound pharmaceutical composition taking isoliensinine and chemotherapeutic drugs as active ingredients, when a bisbenzylisoquinoline natural compound isoliensinine (IsoL) extracted from a traditional Chinese medicine lotus plumule is combined with cytarabine, daunorubicin, adriamycin or dexamethasone for use, a synergistic effect can be achieved when acute leukemia is treated, and the curative effect is good. Therefore, the cell activity of acute leukemia cell lines (Jurkat, U937 and THP1) is obviously inhibited. The isoliensinine and the gemcitabine can play a drug combination effect, so that the activity of colon cancer and gastric cancer cells is remarkably inhibited, and a good application prospect is shown.

Description

technical field [0001] The invention relates to a compound composition, in particular to a compound pharmaceutical composition using isoliensinine and chemotherapeutic drugs as active ingredients. Background technique [0002] Currently commonly used chemotherapy drugs include cytarabine (Ara-C), daunorubicin (DNR), doxorubicin (DOX), dexamethasone (DEX) and gemcitabine (Gemcitabine, GEM), etc. Among them, DNR and Ara-C constitute a "3+7 regimen", which is commonly used in the clinical treatment of AML; DOX is often used for adult AML relapse and rescue treatment. For acute T lymphoblastic leukemia (T cell acute lymphoblasticleukemia, T-ALL), DEX is its general clinical treatment drug; in addition, DOX, DNR and Ara-C can also be used to treat T-ALL. GEM was approved in the United States in 1996 for cancer chemotherapy, and its indications include pancreatic cancer, lung cancer, breast cancer, uterine cancer, and it is also used for the treatment of gastric cancer and lung ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/4725A61K31/7068A61K31/704A61K31/573A61P35/00A61P35/02
CPCA61K45/06A61K31/4725A61K31/7068A61K31/704A61K31/573A61P35/00A61P35/02A61K2300/00Y02A50/30
Inventor 潘扬胡珀杨光明陈景钟蕾葛晓郭亮王歆竹魏震寰
Owner NANJING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com